To the editor,

There are various factors for acute asthma exacerbation.[@B1] A recent article by Cho[@B2] proposed that various therapeutic options should be employed in practice for different causes of asthma exacerbation. Here, we report that sublingual immunotherapy (SLIT) for Japanese cedar pollinosis (JCP) is effective in reducing seasonal asthma worsening. In perennial asthmatics with concomitant JCP, asthma worsening is observed during the pollen season.[@B3] SLIT for rhinoconjunctivitis due to JCP[@B4] was approved in Japan in 2013. However, it remains unclear whether SLIT is effective for asthma observed with JCP.

Forty-seven asthmatics with mild-to-moderate persistent disease who had complicated JCP were enrolled. Fourteen subjects were treated with the SLIT for ≥ 1 year prior to season of cedar pollen of 2018, while 33 were not. This was a retrospective study. Most patients had visited our hospital every 2 months. In this case, medical records of patients who visited in April and May after the pollen scattering season of 2018 were extracted from the medical record. Patients with severe asthma and nonallergic asthma were excluded. Treatments of rhinitis and asthma were performed according to the Japanese guidelines. The SLIT group received a standardized JCP extract (CEDARTOLEN^®^; Torii Pharmaceutical Co., Ltd., Tokyo, Japan) using the protocol of SLIT for JCP.[@B5] Asthma exacerbation was evaluated as defined in the American Thoracic Society/European Respiratory Society statement,[@B6] and only apparent worsening, such as moderate or severe asthma exacerbation, was extracted. Statistical analyses were performed using GraphPad Prism ver. 5.04 (GraphPad Software, San Diego, CA, USA). Two-group comparisons were performed using Pearson\'s χ^2^ tests, and Student *t*-tests or Mann-Whitney *U* tests were used to determine the significance of differences. A *P* value of \< 0.05 was considered statistically significant.

[Table 1](#T1){ref-type="table"} shows the characteristics of patients and clinical outcomes. No difference was observed in either age, sex, sensitized allergens, forced expiratory volume in one second, or asthma therapy between the 2 groups. Thirteen out of the 33 non-SLIT group patients experienced apparent asthma exacerbation during cedar pollen season. In contrast, none of the SLIT-treated group patients showed seasonal asthma exacerbation. The rate of asthma exacerbation was significantly different (*P* \< 0.01) between the 2 groups. As expected, rhinoconjunctivitis symptoms were fewer in the SLIT group (data not shown).

SLIT is effective in some allergic asthma. Marogna *et al.*[@B7] compared the effects of SLIT and inhaled corticosteroids in patients with mild asthma and concomitant rhinitis due to grass pollen allergy, and showed that asthma symptoms decreased significantly in both groups; however, improvements were greater in the SLIT group. We observed that asthma exacerbation during cedar pollen season in Japanese asthmatics with JCP could be sufficiently prevented by SLIT for JCP. Although the presence of limitations, such as the small sample size and the absence of a placebo setting, this study is the first observation indicating that SLIT for JCP certainly attenuates the risk of asthma exacerbation during pollen season. Our results suggest that SLIT for JCP should be more positively considered for patients who suffer from asthmatic worsening during the scattering season of JCP.

This study was approved by the Institutional Review Board (IRB) of Saitama Medical University Hospital (IRB No.18015).

**Disclosure:** Makoto Nagata received honoraria from Astra Zeneca, GSK, Novartis Pharma Ltd., and Torii Pharmaceutical Co., Ltd.

###### Clinical assessment of asthmatics with concomitant JCP and clinical outcomes in asthma exacerbation during cedar pollen scattering season
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  Variables                          All patients                  Non-SLIT        SLIT            *P* value   
  ---------------------------------- ----------------------------- --------------- --------------- ----------- -------
  Patients                           47                            33              14              \-          
  Prevalence of JCP                  100                           100             100             \-          
  Age (yr)                           52.4 ± 17.2                   53.8 ± 18.1     48.9 ± 14.4     0.385       
  Sex                                                                                              0.245       
                                     Male                          12 (25.5)       7 (21.2)        5 (35.7)    
                                     Female                        35 (74.5)       26 (78.8)       9 (64.3)    
  Total IgE (IU/mL)                  241.2 ± 294.3                 246.6 ± 226.8   228.2 ± 414.1   0.176       
  Specific IgE to JCP (UA/mL)        23.1 ± 26.2                   25.2 ± 25.9     17.9 ± 26.1     0.356       
  FEV1 (L)                           2.5 ± 0.8                     2.4 ± 0.8       2.7 ± 0.4       0.880       
  Asthma treatment                                                                                 0.210       
                                     ICS/LABA + LTRA               22 (46.8)       17 (51.5)       5 (35.7)    
                                     ICS/LABA                      15 (31.9)       11 (33.3)       4 (28.6)    
                                     ICS + LTRA                    5 (10.6)        3 (9.1)         2 (14.3)    
                                     ICS                           2 (4.3)         1 (3.0)         1 (7.1)     
                                     Patients without controller   3 (6.4)         1 (3.0)         2 (14.3)    
  Allergens other than JCP                                                                                     
                                     Molds                         7 (14.9)        6 (18.2)        1 (7.1)     0.314
                                     Pollens                       29 (61.7)       21 (63.6)       8 (57.1)    0.749
                                     Pets                          15 (31.9)       13 (39.4)       2 (14.3)    0.086
                                     Mites                         24 (51.1)       19 (57.6)       5 (35.7)    0.212
                                     Insects                       9 (19.1)        5 (15.2)        4 (28.6)    0.248
  Seasonal asthma exacerbation^\*^                                                                 0.004       
                                     Exacerbated                   13 (27.7)       13 (39.4)       0 (0)       
                                     Not exacerbated               \-              20 (60.6)       14 (100)    

Data are shown as mean ± standard deviation or number (%).

JCP, Japanese cedar pollinosis; SLIT, sublingual immunotherapy; IgE, immunoglobulin E; FEV1, forced expiratory volume in one second; ICS, inhaled corticosteroids; LABA, long-acting β~2~ agonist; LTRA, leukotriene receptor antagonist.

^\*^Exacerbation was evaluated based on the American Thoracic Society /European Respiratory Society statement,[@B6] and moderate to severe exacerbation was detected: a deterioration in symptoms and/or lung function with increased rescue bronchodilator use lasting for ≥ 2 days was categorized as moderate, and a need for hospitalization or 2 or more courses of oral corticosteroids was as severe.
